Edition:
India

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Capital Market

1.84USD
1:30am IST
Change (% chg)

$0.03 (+1.38%)
Prev Close
$1.81
Open
$1.86
Day's High
$1.89
Day's Low
$1.76
Volume
54,560
Avg. Vol
25,475
52-wk High
$76.25
52-wk Low
$1.76

Chart for

About

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based... (more)

Overall

Beta: 3.34
Market Cap(Mil.): $53.11
Shares Outstanding(Mil.): 32.18
Dividend: --
Yield (%): --

Financials

BRIEF-Invivo Therapeutics Reports Q1 Loss Per Share Of $3.34

* INVIVO THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

08 May 2018

BRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln Shares

* INVIVO THERAPEUTICS HOLDINGS CORP FILES FOR OFFERING OF UP TO $8 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING Source text (https://bit.ly/2HrYEIM) Further company coverage:

25 Apr 2018

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018

09 Apr 2018

BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™

* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

08 Mar 2018

BRIEF-InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer

* INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

05 Feb 2018

BRIEF-Invivo Therapeutics Says There Is Substantial Doubt About Ability To Continue As A Going Concern

* INVIVO THERAPEUTICS SAYS "THERE IS SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO CONTINUE AS A GOING CONCERN" - SEC FILING

29 Jan 2018

BRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park Capital

* INVIVO THERAPEUTICS ANNOUNCES PURCHASE AGREEMENT FOR UP TO $15 MILLION WITH LINCOLN PARK CAPITAL

26 Jan 2018

BRIEF-InVivo Therapeutics Announces Latest Results From INSPIRE

* INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD

03 Jan 2018

Earnings vs. Estimates